glp 1 and phentermine together What You Need to Know About Semaglutide Phentermine vs. GLP-1 Injections: What's

Description

11 Elevated cortisol can negatively impact metabolism, promote fat storage (especially abdominal fat), disrupt other hormones involved in appetite regulation, increase cravings (particularly for high-sugar, high-fat foods), and contribute to insulin resistance, potentially hindering weight loss efforts despite medication and diet changes

Lisdexamfetamine (Vyvanse) is the only medication specifically approved for moderate to severe BED in adults, typically used alongside psychotherapy

To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe

Conclusion Employers must consider many factors, including costs, compliance, and employee expectations, when determining whether to offer GLP-1 coverage under the health plans they sponsor

A study conducted on 76 patients with advanced CKD (stage 4 or higher) who began semaglutide treatment between January 2018 and January 2023 revealed that many safely reached therapeutic doses